22:58 , Jul 10, 2019 |  BC Extra  |  Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
19:47 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
22:40 , Dec 19, 2018 |  BC Extra  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
23:35 , Apr 5, 2018 |  BC Extra  |  Company News

Management Tracks: CRISPR, Moderna

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) hired Steve Caffé as head of regulatory affairs. Caffé was SVP at Ra Pharmaceuticals Inc. (NASDAQ:RARX). mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) hired Megan Pace as chief...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Annexon completes venture financing

Annexon Biosciences Inc. , Palo Alto, Calif.   Business: Neurology   Date completed: 2016-06-23   Type: Venture financing   Raised: $44 million   Investors: New Enterprise Associates; Correlation Ventures; Novartis Venture Fund; Clarus ; Satter...
00:19 , Jun 24, 2016 |  BC Extra  |  Financial News

Annexon raises $44M in B round

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $44 million in a series B round led by new investor New Enterprise Associates. New investor Correlation Ventures also participated, as did existing investors including Novartis Venture...
01:30 , Jan 14, 2016 |  BC Extra  |  Company News

Management tracks

Rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) hired Mary Szela as CEO. Sandford Smith had been interim CEO since Marc Beer's resignation in July 2015. Szela was CEO of Melinta Therapeutics Inc. (New Haven, Conn.)....
07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Products, hold the platform

While many VCs are pumping record-breaking amounts of capital into big idea platform companies and urging them to fully explore their technologies, Clarus Ventures is sticking with its more measured approach. In addition to keeping...
07:00 , May 18, 2015 |  BioCentury  |  Finance

Planting Fidelity's seeds

Fidelity Biosciences Research Initiative has helped create a neurodegenerative disease company that could serve as a repository for the discoveries stemming from seed investments in academia that FBRI has quietly been making for the past...